|
[1]Ruiz-del-Arbol L, Urman J, Fernandez J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis[J].Hepatology, 2003, 38∶1210-1218.
|
|
[2]Guevara M, Gines P, Fernandez E G, et al.Reversibility of hepalo-renal syndrome by prolonged administration of ornipressin and plasmavolume expansion[J].Hepatology, 1998, 27 (1) ∶35-41.
|
|
[3]Angeli P, Volpin R, Gerunda G, et al.Reversal of type 1 hepatore-nal syndrome with the administration of midodrine and octreotide[J].Hepatology, 1999, 29∶1690-1697.
|
|
[4]Duvoux C, Zanditenas D, Hezode C, et al. Effects of noradrenalin and albumin in patients with type 1 hepatorenal syndrome: A Pilot study[J].Hepatology, 2002, 36∶374-378.
|
|
[5]Moreau R, Durand F, Poynard T, et al.Terlipressin in patients withcirrhosis and type 1 hepatorenal syndrome:A retrospective multi-center study[J].Gastroenterology, 2002, 122∶923-930.
|
|
[6]Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome[J].Hepatology, 2004, 40 (1) ∶55-64.
|
|
[7]Restuccia T, Ortega R, Guevara M, et al.effects of treatment ofhepatorenal syndrome before transplatation on posttrasplatation out-come:A case-control study[J].J Hepatol, 2004, 40 (1) ∶140-146.
|
|
[8]Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment[J].Gastroenterology, 2002, 122∶1658-1676.
|
PDF下载 ( 134 KB)
本文二维码
下载:
